J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III

Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational intravesical drug-releasing system delivering erdafitinib directly to the bladder for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The open-label, multicenter study demonstrated 89% complete response (CR) in intermediate-risk patients with 18-month median duration of response, and 20-month median recurrence-free survival in high-risk patients with 83% 12-month RFS. The localized three-month sustained release approach aims to minimize systemic exposure while maintaining efficacy, supporting ongoing Phase II/III development across risk settings.

Phase I Clinical Results

Study Design:

• Population: Intermediate-risk and high-risk NMIBC with select FGFR alterations
• Treatment: Intravesical erdafitinib-releasing system (Erda-iDRS)
• Duration: Three-month sustained local release

Product Profile & Mechanism

Scientific Rationale:

• FGFR Alterations: Present in ~20% of bladder cancers; drive tumor growth and progression
• Intravesical Advantage: Direct bladder delivery vs. oral systemic administration; reduced toxicity (hyperphosphatemia, dermatologic AEs)
• Sustained Release: Three-month duration reduces treatment frequency vs. standard intravesical BCG or chemotherapy

Strategic Context & Market Opportunity

Competitive Landscape

Development Outlook

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Phase II/III development, FGFR biomarker validation, and competitive positioning for Erda-iDRS in non-muscle-invasive bladder cancer. Actual results may differ due to intravesical delivery technical challenges, FGFR testing adoption, and competitive dynamics with BCG and immunotherapy.-Fineline Info & Tech